Achromobacter xylosoxidans Genomic Characterization and Affecting Clinical Features in Cystic Fibrosis Patients
Extended-Interval Once-Daily Dosing of Aminoglycosides in Adult and Pediatric Patients With Cystic Fibrosis
Infant With Fat-Soluble Vitamin Deficiencies Caused by Cystic Fibrosis
Charities Move Into Role Traditionally Held by Drug Companies
Cystic Fibrosis Foundation Receives $521,000 From BJ's Restaurants, Inc., As Part Of Long-Term Commitment To F
Cystic Fibrosis Foundation Receives $521,000 From BJ's Restaurants, Inc., As Part Of Long-Term Commitment To F
Medical News: Cystic Fibrosis Foundation Receives $521,000 From BJ's Restaurants, Inc., As Part Of Long-Term Commitment To Fight Life-Threatening Disease
Piper Jaffray Names Inspire (ISPH) and Vertex Pharmaceuticals (VRTX) as Top Picks
Hypertrophy Genetics: New hypertrophy genetics study findings have been published by scientists at Washington University, Department of Medicine
Medical News: CREON(R) (pancrelipase) Delayed-Release Capsules Significantly Improves Fat Absorption In Children With Cystic Fibrosis
Cystic Fibrosis Gene Therapy - New cystic fibrosis gene therapy findings from University of North Carolina, Pu
Vertex Pharmaceuticals Reports 2009 Financial Results and Highlights Recent Progress in Hepatitis C and Cystic Fibrosis Development Programs
CREON(R) (Pancrelipase) Delayed-Release Capsules Significantly Improves Fat Absorption in Children with Cystic Fibrosis, Study in Clinical Therapeutics Reports
CREON(R) (Pancrelipase) Delayed-Release Capsules Significantly Improves Fat Absorption in Children with Cystic Fibrosis, Study in Clinical Therapeutics Reports
Telaprevir Update- FDA filing second half of 2010
Telaprevir Update- FDA filing second half of 2010
Vertex Pharmaceuticals Reports 2009 Financial Results and Highlights Recent Progress in Hepatitis C and Cystic Fibrosis Development Programs
InterMune to Participate in Pulmonary-Allergy Drugs Advisory Committee Meeting on March 9, 2010
Phase 2a clinical trial results of VX-809 in patients with CF announced
Vertex Pharmaceuticals Reports 2009 Financial Results and Highlights Recent Progress in Hepatitis C and Cystic Fibrosis Development Programs
